United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,880 shares of the biotechnology company's stock after acquiring an additional 2,889 shares during the quarter. Envestnet Asset Management Inc. owned 0.14% of United Therapeutics worth $21,481,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of UTHR. Wealthfront Advisers LLC lifted its stake in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the period. Norges Bank acquired a new stake in United Therapeutics during the 4th quarter worth about $151,764,000. Thrivent Financial for Lutherans grew its stake in United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock valued at $72,085,000 after purchasing an additional 189,967 shares during the last quarter. AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock worth $66,962,000 after purchasing an additional 161,751 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of United Therapeutics by 28.5% during the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock worth $250,179,000 after purchasing an additional 157,363 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 80,500 shares of company stock valued at $27,849,960 in the last quarter. Insiders own 11.90% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research reports. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $0.46 during trading on Friday, hitting $284.73. 302,945 shares of the company were exchanged, compared to its average volume of 453,066. United Therapeutics Co. has a 12-month low of $233.28 and a 12-month high of $417.82. The company has a fifty day moving average price of $317.98 and a 200-day moving average price of $349.16. The firm has a market capitalization of $12.79 billion, a PE ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the business posted $4.36 EPS. Research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.